Joseph Catanzaro
Stock Analyst at Mizuho
(3.40)
# 993
Out of 5,139 analysts
103
Total ratings
44.05%
Success rate
6.6%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Outperform | $90 → $143 | $120.28 | +18.89% | 4 | Jan 13, 2026 | |
| AVTX Avalo Therapeutics | Initiates: Outperform | $39 | $15.06 | +158.96% | 1 | Dec 18, 2025 | |
| UPB Upstream Bio | Initiates: Outperform | $51 | $31.00 | +64.52% | 1 | Dec 18, 2025 | |
| BCAX Bicara Therapeutics | Initiates: Neutral | $18 | $16.75 | +7.46% | 1 | Dec 18, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $53 | $33.24 | +59.45% | 1 | Dec 18, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $81 → $120 | $69.54 | +72.56% | 2 | Dec 11, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $24 → $30 | $19.21 | +56.17% | 4 | Dec 10, 2025 | |
| CLDX Celldex Therapeutics | Initiates: Outperform | $48 | $25.65 | +87.13% | 1 | Oct 21, 2025 | |
| APGE Apogee Therapeutics | Initiates: Outperform | $105 | $80.77 | +30.00% | 1 | Oct 21, 2025 | |
| IBRX ImmunityBio | Upgrades: Overweight | $4.25 → $5 | $5.52 | -9.42% | 5 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2.5 → $5 | $5.39 | -7.24% | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7.5 → $6 | $2.36 | +154.24% | 10 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $45 | $16.79 | +168.02% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $110 | $124.91 | -11.94% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $38 | $43.96 | -13.56% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $18.86 | -20.47% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $52 → $53 | $71.21 | -25.57% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $10 | $2.88 | +247.22% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.41 | +1,247.52% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $9.83 | +93.29% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.56 | +485.94% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $18.29 | +96.83% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $10.16 | +293.70% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $11.27 | +33.10% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $1.44 | +212.50% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.98 | +1,415.15% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.24 | +1,512.90% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $13.01 | +38.36% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $2.58 | +868.99% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $3.36 | -47.92% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $22.70 | -11.89% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $2.16 | -30.56% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $10.44 | +1,815.71% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $11.60 | +201.72% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.81 | +3,214.92% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.57 | +600.39% | 3 | Apr 7, 2020 |
Revolution Medicines
Jan 13, 2026
Maintains: Outperform
Price Target: $90 → $143
Current: $120.28
Upside: +18.89%
Avalo Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $39
Current: $15.06
Upside: +158.96%
Upstream Bio
Dec 18, 2025
Initiates: Outperform
Price Target: $51
Current: $31.00
Upside: +64.52%
Bicara Therapeutics
Dec 18, 2025
Initiates: Neutral
Price Target: $18
Current: $16.75
Upside: +7.46%
Spyre Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $53
Current: $33.24
Upside: +59.45%
Kymera Therapeutics
Dec 11, 2025
Maintains: Outperform
Price Target: $81 → $120
Current: $69.54
Upside: +72.56%
Nurix Therapeutics
Dec 10, 2025
Maintains: Outperform
Price Target: $24 → $30
Current: $19.21
Upside: +56.17%
Celldex Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $48
Current: $25.65
Upside: +87.13%
Apogee Therapeutics
Oct 21, 2025
Initiates: Outperform
Price Target: $105
Current: $80.77
Upside: +30.00%
ImmunityBio
May 20, 2025
Upgrades: Overweight
Price Target: $4.25 → $5
Current: $5.52
Upside: -9.42%
May 15, 2025
Maintains: Overweight
Price Target: $2.5 → $5
Current: $5.39
Upside: -7.24%
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $2.36
Upside: +154.24%
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $16.79
Upside: +168.02%
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $124.91
Upside: -11.94%
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $43.96
Upside: -13.56%
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $18.86
Upside: -20.47%
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $71.21
Upside: -25.57%
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $2.88
Upside: +247.22%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.41
Upside: +1,247.52%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $9.83
Upside: +93.29%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.56
Upside: +485.94%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $18.29
Upside: +96.83%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $10.16
Upside: +293.70%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $11.27
Upside: +33.10%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $1.44
Upside: +212.50%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.98
Upside: +1,415.15%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.24
Upside: +1,512.90%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $13.01
Upside: +38.36%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $2.58
Upside: +868.99%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $3.36
Upside: -47.92%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $22.70
Upside: -11.89%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $2.16
Upside: -30.56%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $10.44
Upside: +1,815.71%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $11.60
Upside: +201.72%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.81
Upside: +3,214.92%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.57
Upside: +600.39%